NASDAQ:RPRX
Royalty Pharma plc Stock News
$26.62
-0.230 (-0.86%)
At Close: May 24, 2024
Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
08:10am, Wednesday, 21'st Apr 2021
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and se
Royalty Pharma Declares Second-Quarter 2021 Dividend
09:00am, Thursday, 15'th Apr 2021
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A shar
SYF or RPRX: Which Is the Better Value Stock Right Now?
12:53pm, Monday, 12'th Apr 2021
SYF vs. RPRX: Which Stock Is the Better Value Option?
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
09:04am, Thursday, 08'th Apr 2021
Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 mill
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
07:40am, Thursday, 08'th Apr 2021
NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announ
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
07:30am, Thursday, 01'st Apr 2021
NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmi
SYF vs. RPRX: Which Stock Should Value Investors Buy Now?
12:53pm, Thursday, 25'th Mar 2021
SYF vs. RPRX: Which Stock Is the Better Value Option?
The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More
08:36am, Sunday, 28'th Feb 2021
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.
CIXX or RPRX: Which Is the Better Value Stock Right Now?
12:55pm, Tuesday, 23'rd Feb 2021
CIXX vs. RPRX: Which Stock Is the Better Value Option?
Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q4 2020 Results - Earnings Call Transcript
02:40pm, Wednesday, 17'th Feb 2021
Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q4 2020 Results - Earnings Call Transcript
Here's What Caused Royalty Pharma's Mixed Results in Q4
02:00pm, Wednesday, 17'th Feb 2021
The company's royalties revenue soared, but its earnings sank.
Royalty Pharma Reports Q4 2020 and Full-Year Results
07:00am, Wednesday, 17'th Feb 2021
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter of 2020 and introduced full-year 2021 guidance for Adjusted Cash R
Royalty Pharma: Generating Yield In The Biotech Realm
10:40am, Tuesday, 09'th Feb 2021
Royalty Pharma is a unique entity in the healthcare ecosystem. The company is a royalty play as it acquires the rights to either late-stage products or commercially available entities.
Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021
08:00am, Friday, 22'nd Jan 2021
NEW YORK, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter 2020 financial results on Wednesday, February 17, 2021 before the U
Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences
08:30am, Tuesday, 19'th Jan 2021
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva
